GRIA2 and myeloid sarcoma: Surprisingly, the addition of GluA2-G-Gpep normalized the increased expression of both transporters back to control levels (Fig. 3a,b), suggesting that disruption of GluA2-GAPDH interaction could affect astrocyte-specific glutamate transporters in MS.